Our NAFLD model using genetic deletion of Ccr5 aimed to describe the result of a systemic defect of CCR5, whereas pharmacological inhibition of CCR5 through diet might primarily affect the dynamics of microbiota in the gastrointestinal tract. Here, CCR5 is linked to metabolic dysfunction-associated steatotic liver disease.